Real-time computer-generated alerts to select interventions and optimize an antimicrobial stewardship program
IA01
P. DOLCE1, L. BERGERON2, E. LABRECQUE2, A. BOIVIN3, and H. BERNATCHEZ1. 1Department of Medical Microbiology and Infectious Diseases, CSSS Rimouski-Neigette (CSSSRN), 2Department of Pharmacy, CSSSRN, 3Department of Biology, Université du Québec à Rimouski,. ABSTRACT
PATIENTS AND METHODS
Objectives: Implementation of antimicrobial stewardship program (ASP) is a challenge, with limited physician and pharmacist time. A multi-disciplinary approach (clinical pharmacists, medical microbiologists, infectious diseases, information technology) was undertaken to integrate information technology in our ASP, with alerts to tract potential interventions.
•CSSSRN is a 230-beds acute-care regional hospital.
•A total of 1004 alerts were generated by the software, in 686 patients.
•Antibiokos (Nosotech) algorithms were designed and alerts included these core elements
•In comparison to previous year, Antimicrobials consumption (DDD) decreased by 14%, and costs by 34% (Table 1) • A total of 184 interventions were performed in 135 patients (Tables 2, 3).
•overlapping spectra
•Most interventions targeted Quinolones 23%, Pip-Tazo 21%, Cephalosporins 17%, Carbapenems 9%, Macrolides 5%, Antifungals 4%, Antivirals 3%.
•switch from intravenous to oral
•drug optimization according to culture results
•ASP interventions are shown in Table 4. One third of interventions resulted in replacement or discontinuation of therapy (Table 5)
•formulary restriction •pharmacokinetics (PK) •Alerts could be turned off automatically if the antimicrobial changed. Also, one drug could trigger more then one alert. •Interventions were recorded by the ASP team 2 to 4 times weekly.
Vancomycine Valaciclovir
14000
50
Trimethoprim/Sulfamethoxazole Trimethoprim Tobramycin
•All inpatients with oral or parenteral antimicrobials, from December 12, 2015 (P10) to March 31, 2015 (P13) were eligible for ASP intervention targeted with Antibiokos.
45
Tigecycline Rifampicin
43
12000
Posaconazole Piperacillin/Tazobactam
40
Penicillin V oral (PenVee) Penicillin G Parenteral
•Comparison of antimicrobials utilization with previous year was performed, including metrics (DDD, DOT, costs). Voriconazole
Table 1. Antimicrobial consumption per period P10-P13 8545 DDD 118404$ 19609JP
2500
Vancomycin
P10-P13 7348 DDD (-14%) 76548$ (-35%) 19609JP
Antibiokos Implementation
ASP Introduction
Trimethoprim Tobramycin Tetracycline
10000
Nystatin
33
Moxifloxacin Metronidazole
30 8000 25 23
23
6000
21
20
Meropenem
4000
Gentamicin Fluconazole
Daptomycin
15
14
Colistin Cloxacillin Clindamycin
10
Posaconazole
Clarithromycin Ciprofloxacin
2000
Cephalexin
5
Cefuroxime
5
Ceftriaxone
Nitrofurantoin
Ceftazidime
2
Moxifloxacin
1500
Imipenem
Doxycycline
Oseltamivir
2000
Levofloxacin
Ertapenem
Rifampicin
Phenoxymethylpenicillin (PenV)
Linezolid
Erythromycin
20
Trimethoprim/Sulfamethoxazole
Piperacillin/Tazobactam
Defined Daily Doses
Oseltamivir
35
0
0
Cefprozil
0
0
Metronidazole
Cefoxitin
Meropenem
Cefotaxime
Linezolid
Cefazolin
Levofloxacin
Caspofungin
Itraconazole
Azithromycin
Isoniazid
Ampicillin
Imipenem
Amphotericin B
Gentamicin
Amoxicillin/Clavulinic Acid
Fluconazole
Amoxicillin
Ethambutol
Aciclovir
Erythromycin
Interv
Ertapenem Doxycycline Daptomycin
1000
Table 4. ASP Interventions
Cloxacillin Clindamycin Clarithromycin Ciprofloxacin Cefuroxime Ceftriaxone Ceftazidime Cefprozil
INTRODUCTION
Voriconazole
Table 3. Antimicrobial Utilization and Interventions per ward
Minocycline
Conclusions: Realtime alerts provided a powerful tool to our ASP, with significant reduction of antimicrobial consumption and cost reduction
•The software provided significant time-reduction with estimates : >95% to get the metrics (DDD or DOT), and >50% to target and perform ASP interventions.
Interventions
Outcomes: During the first 4 months, a total of 7348 DDD were observed among inpatients, and 1004 electronic alerts were generated in 686 patients. The alerts were time-sensitive stop orders 55%, restriction 12%, PK 10%, optimization according to culture 6%, switch IV to oral 6%, overlapping spectra 6%, other 4%. A total of 184 interventions were done in 135 patients, mainly on Quinolones 23%, Pip-Tazo 21%, Cephalosporins 17%, Carbapenems 9%, Macrolides 5%, Antifungals 4%, Antivirals 3%. Suggestions were: no change 65%, replacement 23% and stop 12%. High acceptance rate of suggestions (95%) was observed. In comparison to the previous year, DDD were reduced by 14% and costs by 34%. The software provided significant time-reduction with estimates : >95% to get the metrics (DDD or DOT), and >50% to target and perform ASP interventions.
• time-sensitive stop orders (3 days for IV, 7 days for oral)
DDD/1000 patient-days
Methods: CSSSRN is a tertiary regional hospital with 230 acute-care beds. A software “Antibiokos” was implemented in November 2014 to enable our ASP team to tract interventions, using real-time data from interfaces with pharmacy, microbiology laboratory and admission-discharge-transfer. Electronic algorithms included core elements of ASP such as: time-sensitive stop orders (3 days for IV, 7 days for oral), overlapping spectra, switch from intravenous to oral, drug optimization according to culture results, formulary restriction and pharmacokinetics (PK). Real-time metrics (DDD, DOT, Costs) were provided.
RESULTS
Cefoxitin
500
Cefotaxime Cefixime Cefazolin Cefalexin
Pharmacokinetics 16 9%
Switch IV to oral 30 18%
Formulary restriction 9 5%
Overlapping spectra 7 4% Physician request 1 1%
Table 5. Intervention Results
Replacement 43 23%
Stop 22 12%
Caspofungin Azithromycin Ampicillin
0 1
2
3
4
5
6
7
8
9
10
11
12
13
1
2
3
4
5
6
7
8
9
10
11
12
Amoxicillin/Clavulinic Acid
Periods
Amoxicillin
2013-2014
2014-2015
•However, measurements of metrics was cumbersome, and it was difficult to record interventions.
Aciclovir
45
1000
Emergency Room
30 600
DDD
25 500
20 17
400
300
3
2 0
0
0
1
0
2 0
1
3
2 0
0
0
2
3
4
5 2
0
0
0
0
0
0
0
1
0
Trimethoprim
Tobramycin
Tigecycline
Rifampicin
Posaconazole
Piperacillin/Tazobactam
Penicillin V oral (PenVee)
Penicillin G Parenteral
Oseltamivir
Nystatin
Moxifloxacin
Metronidazole
Meropenem
Linezolid
Levofloxacin
Imipenem
Gentamicin
Fluconazole
Erythromycin
Ertapenem
Doxycycline
Daptomycin
Colistin
Cloxacillin
Clindamycin
Clarithromycin
Ciprofloxacin
Cephalexin
Cefuroxime
Ceftriaxone
Ceftazidime
Cefprozil
Cefoxitin
Cefotaxime
Cefazolin
Caspofungin
Azithromycin
Ampicillin
Amphotericin B
Amoxicillin/Clavulinic Acid
Amoxicillin
Aciclovir
0
Other authors : none
5C Surgery 5A Psychiatry 4C Orthopedics
3C Oncology
6
2
2
2C Medicine - Geriatrics
• Information technology greatly improved the efficiency of our ASP team, with friendly-user software. • Realtime alerts provided a powerful tool to our ASP, with significant reduction of human resources, antimicrobial consumption and cost reduction.
2A Cardiology 0
0 Voriconazole
4
5
Vancomycine
1
5
10
Valaciclovir
5
4
3
9
8
Trimethoprim/Sulfamethoxaz…
9
6C Pediatrics
4A OBG
11
DISCUSSION AND CONCLUSIONS
NICU
27
200
Conflict of interest : P Dolce is President of Nosotech Inc.
ICU
35
700
100
No change 119 65%
40
15
•This retrospective study presents the results of the Pilot Study.
Time-sensitive stop orders 96 57%
40
900
800
•Algorithms were designed to tract interventions opportunities.
Optimization according to cultures 8 5%
Optimization according to guidelines 1 1%
Table 2. Utilization and Interventions per antimicrobial
•Information technology with artificial intelligence has the potential to provide useful realtime assistance to ASP teams. •A pilot study was undertaken with the introduction of Antibiokos software (with realtime data from interfaces with Admission-Discharge-Transfer, Microbiology Lab and Pharmacy systems) in November 2014.
Amphotericin B
13
Interventions
•An ASP program was implemented in our facility with a pharmacist 12 hours/week and Infectious Disease specialist 3 hours/week in September 2014.
Benzylpenicillin (Pen G)
1C Psychiatry Interventions
Correspondence, reprints or requests to: Dr Patrick Dolcé MD FRCPC Department of Medical Microbiology and Infectious Diseases CSSS Rimouski-Neigette 150, Rouleau Rimouski, Québec Canada, G5L 5T1 Telephone (418) 724-3000 #8336 Fax (418) 724-8619 e-mail:
[email protected]